Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 48 results for "julie masow"

Novartis combination therapy Tafinlar® + Mekinist® demonstra...

/PRNewswire/ -- Novartis today announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive advanced melanoma when treated with the first-line combination of Tafinlar® (dabrafenib) + ... TickerTech.com, 3 weeks ago

Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer

/PRNewswire/ -- Novartis today announced new data for multiple investigational and established non-small cell lung cancer (NSCLC) treatments, including results from a pivotal, Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist® ...
 TickerTech.com3 weeks ago

Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®

/PRNewswire/ -- Novartis today announced at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting, the first results from the Tasigna (nilotinib) Treatment-free Remission (TFR) clinical trial program. These studies evaluated the ...
 TickerTech.com3 weeks ago
[x]  

Novartis announces US collaboration to co-promote Lenvima® in combination with everolimus for advanced renal cell carcinoma (RCC)

/PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced an agreement with Eisai Inc. to collaborate on commercial and certain medical affairs activities in the United States (US) to co-promote Lenvima* (lenvatinib) capsules used in ...
 TickerTech.com3 weeks ago
[x]  

Colombia Threatens to Override Novartis's Patent on Gleevec

By Kejal Vyas BOGOTÁ -- Colombia's government will override Novartis's patent on a cancer medication by the end of May and open it up to generic manufacturers unless the Swiss pharmaceutical giant accepts a price cut, the country's health minister ...
 4 Traders1 month ago
[x]  

Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting

/PRNewswire/ -- Novartis will highlight the strength of its oncology research programs at the upcoming 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), being held June 3-7 in Chicago. Data will demonstrate advances across ...
 TickerTech.com1 month ago
[x]  
TeleTrader.com

MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer

Novartis International AG / . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Independent Data Monitoring Committee recommends stopping the trial early as it met ...
 Bloomberg1 month ago MONALEESA-2 trial of Novartis LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer  PharmaVOICE1 month ago
[x]  

Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex

/PRNewswire/ -- Novartis today announced results from a Phase III study showing Afinitor®* (everolimus), when used as an adjunctive therapy, significantly reduced treatment-resistant seizures associated with tuberous sclerosis complex (TSC) ...
 TickerTech.com2 months ago
[x]  
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less